The benefit of a clinical history and a compound developed when broadness of activity was the goal. Most drugs developed today are highly specialized to a gene or protein. Bisantrene is one of the most sensitive agents I have seen because of how broadly targeting it is. Wonder what happens when you use it properly.
Here are the tumor agnostic approved drugs.
Tumor Agnostic Therapies Drug NameLarotrectinib (Vitrakvi)Entrectinib (Rozlytrek)Repotrectinib (Augtyro)Pembrolizumab (Keytruda)Dostarlimab (Jemperli)Dabrafenib and Trametinib (Tafinlar & Mekinist)Selpercatinib (Retevmo)Fam-trastuzumab deruxtecan (Enhertu)
Intellectual Property (IP) Waterproofing., page-24
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.48 |
Change
0.035(2.43%) |
Mkt cap ! $251.4M | |||
| Open | High | Low | Value | Volume |
| $1.44 | $1.48 | $1.44 | $11.37K | 7.761K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1348 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 800 | 1 |
View Market Depth
| Last trade - 10.27am 01/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |